🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/JWTPUViFkI https://t.co/DsKunA4DkQ

Worsening Breathlessness in SSc ILD Dr. Aurelie Najm, Glasgow, presents a QD Clinic on worsening breathlessness in systemic sclerosis interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/P3MoM7ZmIo

GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated. https://t.co/x2soZxuZCO https://t.co/84lnQOzsvP

What you need to know about scleroderma-related lung fibrosis What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? https://t.co/Ezl5G5IZeI https://t.co/zTF4lIYCAJ

New Multidisciplinary Classification of the Interstitial Pneumonias: ATS/ERS Guideline. https://t.co/HWteOikGXT 🫁🩻🎞⚔️🐍🧪🔬💡📚 @ERSpublications @EuroRespSoc @ALATorax @SPLF_SocPneumo @pneumosbpt @NeumoMadrid @SeparRespira @HUReinaSofia @neumoparatodos @Neumosur @NeumoNat https://t.co/GnJjuxMIEm

Verba Volant, Scripta Manet - Latin proverb meaning "spoken words fly away, written words remain", https://t.co/gXgDR7YS0C

Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/BebFhDJ1mM

Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh